Edition:
United States

OncoSec Medical Inc (ONCS.OQ)

ONCS.OQ on NASDAQ Stock Exchange Capital Market

1.66USD
19 Apr 2018
Change (% chg)

-- (--)
Prev Close
$1.66
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
170,529
52-wk High
$2.95
52-wk Low
$0.88

Latest Key Developments (Source: Significant Developments)

Oncosec Medical Prices $20 Mln Public Offering Of Common Stock
Thursday, 1 Feb 2018 09:21am EST 

Feb 1 (Reuters) - Oncosec Medical Inc ::PRICES $20.0 MILLION PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 13.3 MILLION COMMON SHARES PRICED AT $1.50PER SHARE.  Full Article

Oncosec Plans To Conduct A Second Clinical Trial In Triple Negative Breast Cancer In 2018​
Wednesday, 3 Jan 2018 08:00am EST 

Jan 3 (Reuters) - Oncosec Medical Inc ::ONCOSEC PROVIDES 2018 BUSINESS OUTLOOK.ONCOSEC MEDICAL INC - PLAN TO CONDUCT A SECOND CLINICAL TRIAL IN TRIPLE NEGATIVE BREAST CANCER IN 2018​.ONCOSEC MEDICAL -‍PLAN TO CONDUCT 2 INVESTIGATOR SPONSORED TRIALS IN SQUAMOUS CELL CARCINOMA OF HEAD, NECK AND IN MELANOMA NEOADJUVANT SETTING IN 2018​.ONCOSEC MEDICAL INC - PREPARE TO COMMERCIALLY LAUNCH IMMUOPULSE IL-12 IN U.S. IN 2018.  Full Article

Oncosec Announces Dosing Of First Patient In Registration-Directed Phase 2B Clinical Trial
Thursday, 14 Dec 2017 08:00am EST 

Dec 14 (Reuters) - Oncosec Medical Inc ::ONCOSEC ANNOUNCES DOSING OF FIRST PATIENT IN REGISTRATION-DIRECTED PHASE 2B CLINICAL TRIAL, PISCES/KEYNOTE-695, OF IMMUNOPULSE® IL-12 IN COMBINATION WITH PEMBROLIZUMAB.  Full Article

OncoSec Medical files for offering of up to 6.83 mln shares
Thursday, 16 Nov 2017 08:59am EST 

Nov 16 (Reuters) - Oncosec Medical Inc -:OncoSec Medical Inc files for offering of up to 6.83 million shares of co's common stock by the selling shareholders - SEC filing.  Full Article

Oncosec announces positive follow-up data from phase 2 trial of Immunopulse il-12
Wednesday, 8 Nov 2017 07:30am EST 

Nov 8 (Reuters) - Oncosec Medical Inc :Oncosec announces positive updated long-term follow-up data from phase 2 trial of Immunopulse il-12 in combination with pembrolizumab demonstrating a progression free survival rate (PFS) of 57% at 15 months in predicted anti-pd-1 non-responder melanoma p.  Full Article

Oncosec appoints Daniel O'Connor as CEO
Tuesday, 7 Nov 2017 05:04pm EST 

Nov 7 (Reuters) - Oncosec Medical Inc :Oncosec appoints Daniel J. O'Connor as chief executive officer to lead next stage of growth as a fully integrated late stage development and commercial company.Oncosec medical - ‍punit Dhillon, co-founder of Oncosec, will continue to serve as company's president and a member of its board​.  Full Article

Intracoastal Capital LLC reports 7.5 pct passive stake in OncoSec Medical
Tuesday, 31 Oct 2017 05:00pm EDT 

Oct 31 (Reuters) - OncoSec Medical Inc :Intracoastal Capital LLC reports 7.5 pct passive stake in OncoSec Medical Inc, as of October 22, 2017‍​.  Full Article

OncoSec Q4 loss per share $0.28
Wednesday, 25 Oct 2017 04:15pm EDT 

Oct 25 (Reuters) - OncoSec Medical Inc : :OncoSec announces fourth quarter and year end financial results for fiscal year 2017.Q4 loss per share $0.28.OncoSec medical - ‍expects current funds to be sufficient to allow co to continue to operate business to third calendar quarter of 2018​.  Full Article

Oncosec Q3 loss per share $0.22
Thursday, 1 Jun 2017 04:01pm EDT 

June 1 (Reuters) - Oncosec Medical Inc ::Oncosec announces third quarter and ytd results for fiscal year 2017.Q3 loss per share $0.22.Q3 earnings per share view $-0.28 -- Thomson Reuters I/B/E/S.  Full Article

Oncosec Q2 loss per share $0.27
Thursday, 16 Mar 2017 04:01pm EDT 

Oncosec Medical Inc : Oncosec announces second quarter and ytd results for fiscal year 2017 .Q2 loss per share $0.27.  Full Article

BRIEF-Oncosec Medical Prices $20 Mln Public Offering Of Common Stock

* SAYS PUBLIC OFFERING OF 13.3 MILLION COMMON SHARES PRICED AT $1.50PER SHARE Source text for Eikon: Further company coverage: